Neural interface medtech · Pre-Seed round

Your Mind, Encrypted.
Your World, Connected.

PCYLINK is building an injection-delivered, self-assembling nanostructure mesh that captures high-fidelity neural signals, encrypts them at the source, and routes motor intent wirelessly to external devices — restoring communication and control for patients with severe motor impairment, without open-skull surgery.

Raising a $2.0M Pre-Seed Round to complete nanomaterial synthesis, benchtop validation, and in vitro proof-of-concept in 18 months. Founder: Kean A. Morton.

$2.0M Pre-Seed Clinical-first Source encryption NeuraSense demo live

Problem · three failure points

The Problem

Healthcare systems and payers waste over $10 billion annually managing severe paralysis across 300,000+ U.S. patients through high-risk $150,000+ open craniotomies and prolonged intensive care complications.

01 Failure point

Extreme Surgical Risk

Traditional BCIs require drilling through the skull (craniotomy), with significant risk of infection, chronic inflammation, and scar-tissue buildup.

→ Solved by Minimally Invasive Delivery

02 Failure point

Prohibitive Healthcare Cost

Open-skull neurosurgery costs hospital systems and payers over $150,000 per procedure, limiting accessibility to only extreme edge cases.

→ Solved by Cost-Effective Outpatient Economics

03 Failure point

Unprotected Neural Data

Most neural recording systems prioritize signal over security, leaving raw neural data exposed to privacy risks and potential attack vectors.

→ Solved by Hardware-Grade Source Encryption

The result: neural interfaces stay confined to a small number of specialized centers — out of reach for most of the patients who need them.

Solution · one answer per failure point

The Solution

PCYLINK delivers high-fidelity brain-computer interfacing through a minimally invasive, non-craniotomy delivery system with hardware-grade source encryption.

01 Solves 01

Minimally Invasive Delivery

Replaces open-skull surgery with a targeted micro-injection, drastically reducing infection risk, tissue trauma, and patient recovery time.

← Answers Extreme Surgical Risk

02 Solves 02

Cost-Effective Outpatient Economics

Lowers procedure complexity and hospital stay times, cutting overall delivery costs by more than 60% compared to traditional craniotomies.

← Answers Prohibitive Healthcare Cost

03 Solves 03

Hardware-Grade Source Encryption

Encrypts neural signals at the biological interface before transmission, designed to prevent unauthorized interception.

← Answers Unprotected Neural Data

One platform, three answers: injection delivery, outpatient economics, and encryption at the source — built for the severe motor impairment beachhead.

Critical path · three steps

How It Works

PCYLINK captures high-fidelity neural signals through a minimally invasive interface, encrypting and routing data directly to external systems without open-skull surgery.

1

Minimally Invasive InjectionThe Delivery

Delivered via a standard systemic or targeted micro-injection, completely bypassing surgical craniotomy and vascular catheterization.
Formulated with biocompatible, self-assembling nanoscale materials engineered to cross the targeted barrier and interface directly with local neural tissue.

2

In Situ Mesh Formation & Energy HarvestingThe Interface

Once localized, the nanoscale elements assemble into a flexible, conductive micro-mesh that integrates seamlessly across neural cellular architecture without mechanical tissue damage.
The system utilizes integrated bio-electrochemical energy harvesting (bio-battery architecture), utilizing surrounding biological substrates to power the telemetry network internally.

3

Signal Acquisition & Encrypted TransmissionThe Telemetry

The assembled mesh records micro-volt neural potentials and encrypts the raw signal directly at the biological source.
Data transmits wirelessly to external paired hardware, enabling high-fidelity digital and physical device control.

The Clinical Outcome:

Patients regain lost physical agency and high-speed digital control through an outpatient-style intervention that bypasses the severe risks of invasive brain surgery.

Live product simulation

NeuraSense — See the Neural Mesh in Action

Open now

pcylink.com/neurasense

An interactive simulation of the PCYLINK platform: a neural mesh decoding intent and routing encrypted commands to personal, mobility, and medical devices.

Device control — phones, laptops, wheelchairs, vehicles, robots, and medical devices
Assistive focus — control when hands or voice are unavailable
Secure sessions — each connection encrypted before commands reach a device
Tap to focus — select a device to highlight its link in the mesh

Why it matters

A live product surface investors and clinicians can explore today, ahead of preclinical data.

Safety · security · preclinical plan

Safety & Security by Design

01 · Clinical safety

Minimally invasive, biocompatible

No open craniotomy — a targeted micro-injection reduces surgical trauma, scarring, and recovery time.
Flexible mesh — biocompatible, self-assembling nanomaterial with chronic tissue-response mitigation built into the design.
Defined benchmarks — biocompatibility and signal-capture criteria set before in vivo work begins.

02 · Neural data security

Encrypted at the biological source

Encrypted at capture — proprietary telemetry protocols encrypt neural data before it leaves the body.
Fresh keys every session — AES-256 plus Neural-Ephemeral Key Exchange (NEKE) gives each connection its own key.
Patient-owned, isolated — data treated as the patient’s asset; wireless functions separated from core biological functions.

01

Pre-Seed · phase 1

Bench fabrication

Micro-mesh prototypes and delivery mechanics.

02

Pre-Seed · phase 2

Biocompatibility

In vitro testing against defined benchmarks.

03

Next round

In vivo validation

Non-primate studies of delivery and signal capture.

04

Next round

FDA Q-Submission

Lock the regulatory path toward an IDE.

Differentiator: no implant competitor publishes an end-to-end neural-data encryption design. Utility patent filings on the encryption architecture are a Pre-Seed milestone.

Market · current drain → beachhead → expansion

Market Opportunity

PCYLINK converts a $10B annual healthcare drain into a $15B clinical beachhead, expanding into a $38B global neurotechnology market by 2032.

01 · The Beachhead

Redirecting Current Spend

$10B

Annual SCI + ALS care drain

300,000

U.S. patients eligible for motor restoration

$15B

U.S. clinical beachhead

$900M

Recurring procedure market / year

The Current Drain: $10B per year spent on lifelong care, hospitalization and complications for SCI and ALS patients.
PCYLINK Opportunity ($15B beachhead): 300,000 patients in the U.S. eligible for motor restoration × $50,000 procedure price (substantially lower than a $150k open craniotomy).
Annual Incident Flow: 18,000 new severe neurological trauma and ALS cases annually represent an immediate $900M/year recurring procedure market.

02 · The Expansion

Global Neurotechnology

$38B

Global TAM by 2032

Total Addressable Market (TAM): $38 Billion global neurotechnology market by 2032, spanning neurostimulation, neurosensing, neuroprostheses and neurorehabilitation.
The Catalyst: Today that $38B market is bottlenecked by open-skull surgery risk. By eliminating craniotomy, PCYLINK expands patient candidacy and unlocks outpatient adoption across regional surgical centers.

$10B annual SCI + ALS care drain (Slide 2)→$15B U.S. clinical beachhead→$38B global neurotechnology TAM by 2032

Competition · head-to-head

Competitive Landscape

PCYLINK eliminates the surgical trauma of Neuralink and the channel-count limits of Synchron by utilizing injectable nanomaterials with hardware-grade encryption.

Capability	Neuralink	Synchron	PCYLINK Advantage (Target)
Surgical Invasiveness & Delivery	Highly invasive. Requires a craniectomy (a coin-sized section of skull removed) and robotic insertion of penetrating electrode threads into the cortex.	Moderately invasive. Endovascular catheter delivery via the jugular vein (stent-based), plus a subcutaneous chest pocket for the telemetry unit.	Minimally invasive targeted injection. Zero surgical bone removal, zero vascular catheterization.
Signal Density & Cellular Integration	High channel count (1,024 electrodes on flexible threads), but penetrating electrodes provoke a tissue response; thread retraction cut effective electrodes in the first patient.	Lower channel density (16 electrodes), restricted to recording from within large blood vessels outside the actual parenchyma.	Distributed nanoscale mesh. Self-assembles directly at the neural cellular level, enabling high-resolution capture without rigid tissue displacement.
Long-Term Biocompatibility & Power	Small rechargeable battery inside the skull-mounted implant; requires routine inductive recharging through the scalp.	No implanted battery; chest-implanted telemetry unit depends on an external inductive power unit worn over it.	In situ biochemical energy harvesting. Powered by native biological substrates, eliminating bulky battery hardware and chronic tissue-strain.
Architecture & Data Security	On-implant spike detection and compression, then Bluetooth to an external app for decoding.	Raw signals relayed over a custom RF link from the chest unit; decoding happens off-body.	Hardware-grade source encryption. Telemetry is encrypted directly at the biological interface, protecting neural privacy at the origin.
Architecture & Data Security	Neither publishes an end-to-end neural-data encryption design.

Status · technical validation

Current Status & Technical Validation

PCYLINK has completed in silico computational modeling and IP groundwork, positioning the company to transition directly into wet-lab bench synthesis.

01 · In silico phase

De-Risking Milestones Completed (In Silico Phase)

Computational Biophysics & Modeling

Completed theoretical simulations modeling nanomaterial self-assembly dynamics, molecular transport, and baseline electrical conductivity in simulated neural environments.

Biochemical Energy Harvesting Thesis

Modeled in situ bio-electrochemical power generation to calculate power draw and thermal dissipation limits for the internal network.

Intellectual Property Foundation

Filed core trademarks (PCYLINK™) and drafted provisional patent claims covering injectable self-assembling neural interfaces and bio-source encryption.

Preclinical Trial Protocol

Designed comprehensive in vitro and non-primate in vivo testing protocols alongside clear FDA pre-submission milestones.

02 · Pre-seed capital deployment

The Next Horizon (Pre-Seed Capital Deployment)

Current Stage

Now

In Silico (Simulation & Theoretical Architecture).

$2.0M Pre-Seed · 18 months

Funded Stage · Pre-Seed

This round

In Vitro (Physical Nanomaterial Synthesis and Bench Biocompatibility Testing).

$8M–$10M institutional round

Next Stage · Institutional Seed

Team · leadership & hiring plan

Team & Scientific Architecture

PCYLINK is led by proprietary systems architecture and supported by an immediate roadmap to seat world-class neuroengineering and clinical leadership.

01 · Founder

Core Leadership

Kean Morton

Founder & Systems Architect

Lead architect of PCYLINK neural networking protocols, encrypted brain-computer interface architecture, and proprietary signal transmission thesis. Spearheading initial IP filing, investor formation, and technical development roadmap. Directed PCYLINK’s in silico simulation and modeling program.

02 · Pre-seed team & lab

Pre-Seed Team & Lab Partnerships (Funded This Round)

Principal Materials Scientist

Pre-Seed Hire

Leads nanomaterial formulation, characterization, and electrical conductivity verification for the self-assembling mesh.

Electrophysiology Researcher

Pre-Seed Hire

Dedicated to baseline bio-electrical signal transmission testing on benchtop neural tissue cultures.

Next Round (Institutional Seed)

Next round

Chief Scientific Officer / Lead Neurobiologist · VP of Biomaterials & Neural Engineering · Lead Regulatory & FDA Strategist, for in vivo validation and the FDA pathway.

Commercialization · pricing

Go-to-Market & Commercial Model

PCYLINK enters the market via established neurotechnology reimbursement pathways, monetizing through high-margin medical device sales and hospital procurement.

01 · Pathway

Commercialization Pathway

1

Clinical Beachhead

Focus strictly on severe motor impairment and paralysis restoration, pursuing FDA Breakthrough Device designation and expedited review pathways.

2

Payer Reimbursement (CPT / DRG)

Modeled after proven neuromodulation billing pathways (such as Deep Brain Stimulation and spinal cord stimulation), covered by Medicare and private insurers.

3

Procurement Target

Tier 1 neurosurgical centers and specialized rehabilitation hospitals that already purchase and deploy implantable neural hardware.

02 · Economics

Unit Economics & Pricing Model

$45K–$65K

Target price per unit

Sub-$3K

Target COGS at scale

90%+

Hardware gross margin

Target Procedure Price: $45,000 to $65,000 per unit (benchmarked against traditional invasive neuromodulation implants).
Target Device COGS: Sub-$3,000 at scaled production, driving 90%+ gross margins on hardware.
Secondary Revenue Stream (Phase 2): Secure neural telemetry and API software licensing fees for specialized assistive robotics and external interface hardware.

Financials · capitalization

Financial Model & Capitalization Roadmap

~$28M

Cumulative capital
through first revenue

PCYLINK requires ~$28M in cumulative capital through first commercial revenue, across three development phases, to reach FDA PMA approval via the Breakthrough pathway and scale to $20M in commercial procedure revenue by Year 5.

01 · Operating plan

5-Year Operating & Capital Plan

Year · Phase	Operating Burn	Revenue	Focus
Year 1Pre-Seed PhaseThis round	$2.0M	$0	Nanomaterial formulation, in vitro benchtop biocompatibility, and utility patent portfolio.
Year 2Institutional Seed Phase	$6.0M	$0	Non-primate in vivo animal models, signal-to-noise optimization, and FDA Q-Submission / IDE filing.
Year 3Series A / Clinical Trials	$10.0M	$0	First-in-human feasibility safety study (10–15 patients) and IDE trial execution.
Year 4Early Commercialization	$10.0M	$3.0M	FDA PMA approval (Breakthrough pathway), early access programs across 3 pilot neurosurgical centers (60 injections @ $50k).
Year 5Scaled Commercial Adoption	$12.0M	$20.0M	Expanded commercial rollout across 20 Tier-1 hospital networks (400 injections @ $50k, 88% gross margins). Reaches operating profitability in Year 5.
Years 1–4	$28.0M	$3.0M	Cumulative operating burn through first commercial revenue ($2.0M + $6.0M + $10.0M + $10.0M).

02 · Assumptions

Key Financial Assumptions

Procedure ASP

$50,000

Blended price per implant system, reimbursed via established neurotechnology pathways.

Target COGS

$6,000 per unit

At early production, driving 88% gross margin.

Cumulative Capital Through First Commercial Revenue

~$28M

Across Pre-Seed, Seed, and Series A rounds (Years 1–4 operating burn).

Operating Profitability

Year 5

Reaches operating profitability in Year 5.

Pre-seed round · use of funds

The Ask & Milestones

$2.0M

Pre-Seed Round
18-month horizon

PCYLINK is raising a $2.0M Pre-Seed Round to complete physical nanomaterial synthesis, benchtop validation, and initial in vitro proof-of-concept over 18 months.

01 · Use of funds

Allocation of Funds ($2,000,000)

$1.0M—

Wet-Lab Synthesis & Benchtop R&D

50%

Nanomaterial formulation, characterization, electrical conductivity verification, and in vitro cell-culture biocompatibility assays.

$600K—

Core Scientific Team & Lab Partnerships

30%

Sponsored university lab access, principal materials scientist, and dedicated electrophysiology researcher.

$400K—

IP Portfolio & Regulatory Architecture

20%

Formal conversion of provisional patents to PCT/utility filings, and initial regulatory engagement strategy.

02 · Milestones

Milestones Unlocked (Pre-Seed Horizon)

Milestone 1

Physical Nanomaterial Synthesis

Confirmed in vitro self-assembly of conductive nanostructures in simulated bio-environments.

Milestone 2

Bench Biocompatibility

Validated non-toxicity and baseline bio-electrical signal transmission on benchtop neural tissue cultures.

Milestone 3

Utility Patent Portfolio

Filed utility patent applications covering the injectable self-assembling mesh and biochemical energy harvesting.

Milestone 4

Institutional Seed / Series A De-Risking

Direct biological proof in hand, unlocking an institutional $8M–$10M round for in vivo animal models and FDA engagement.

Join the $2.0M Pre-Seed Round

Your Mind, Encrypted.
Your World, Connected.

$2.0M Pre-Seed · In vitro proof-of-concept · Utility patents · 18 months

Partner with PCYLINK to bring minimally invasive, encrypted neural interfaces to patients with severe motor impairment.

Founder Kean A. Morton

Email Keanam@pcylink.com

Web pcylink.com

Demo pcylink.com/neurasense

Your Mind, Encrypted.Your World, Connected.

The Problem

Extreme Surgical Risk

Prohibitive Healthcare Cost

Unprotected Neural Data

The Solution

Minimally Invasive Delivery

Cost-Effective Outpatient Economics

Hardware-Grade Source Encryption

How It Works

Minimally Invasive InjectionThe Delivery

In Situ Mesh Formation & Energy HarvestingThe Interface

Signal Acquisition & Encrypted TransmissionThe Telemetry

NeuraSense — See the Neural Mesh in Action

Safety & Security by Design

Minimally invasive, biocompatible

Encrypted at the biological source

Bench fabrication

Biocompatibility

In vivo validation

FDA Q-Submission

Market Opportunity

Redirecting Current Spend

Global Neurotechnology

Competitive Landscape

Current Status & Technical Validation

De-Risking Milestones Completed (In Silico Phase)

Computational Biophysics & Modeling

Biochemical Energy Harvesting Thesis

Intellectual Property Foundation

Preclinical Trial Protocol

The Next Horizon (Pre-Seed Capital Deployment)

Current Stage

Funded Stage · Pre-Seed

Next Stage · Institutional Seed

Team & Scientific Architecture

Core Leadership

Pre-Seed Team & Lab Partnerships (Funded This Round)

Principal Materials Scientist

Electrophysiology Researcher

Sponsored University Lab

Next Round (Institutional Seed)

Go-to-Market & Commercial Model

Commercialization Pathway

Clinical Beachhead

Payer Reimbursement (CPT / DRG)

Procurement Target

Unit Economics & Pricing Model

Financial Model & Capitalization Roadmap

5-Year Operating & Capital Plan

Key Financial Assumptions

The Ask & Milestones

Allocation of Funds ($2,000,000)

Wet-Lab Synthesis & Benchtop R&D

Core Scientific Team & Lab Partnerships

IP Portfolio & Regulatory Architecture

Milestones Unlocked (Pre-Seed Horizon)

Physical Nanomaterial Synthesis

Bench Biocompatibility

Utility Patent Portfolio

Institutional Seed / Series A De-Risking

Your Mind, Encrypted.Your World, Connected.

Your Mind, Encrypted.
Your World, Connected.

Your Mind, Encrypted.
Your World, Connected.